L3VLUP
ProSign in

RARE · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RAREJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RARE
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterRAREJNJ
Q3 20206 holders, $1.6bn30 holders, $26.2bn
Q4 20208 holders, $3.0bn32 holders, $26.6bn
Q1 202110 holders, $2.6bn31 holders, $25.3bn
Q2 202114 holders, $2.3bn37 holders, $25.6bn
Q3 20219 holders, $2.0bn40 holders, $24.1bn
Q4 20218 holders, $1.6bn33 holders, $25.2bn
Q1 20228 holders, $1.5bn35 holders, $28.2bn
Q2 20228 holders, $1.1bn33 holders, $26.9bn
Q3 20226 holders, $487m36 holders, $25.4bn
Q4 20228 holders, $604m35 holders, $27.6bn
Q1 20239 holders, $502m42 holders, $24.5bn
Q2 202311 holders, $619m38 holders, $25.0bn
Q3 20238 holders, $397m37 holders, $18.9bn
Q4 20239 holders, $593m31 holders, $19.0bn
Q1 202412 holders, $513m32 holders, $19.7bn
Q2 202413 holders, $413m35 holders, $20.4bn
Q3 202416 holders, $809m28 holders, $22.3bn
Q4 202411 holders, $243m37 holders, $20.4bn
Q1 20258 holders, $158m32 holders, $20.5bn
Q2 20257 holders, $120m31 holders, $18.4bn
Q3 20258 holders, $94m32 holders, $23.7bn
Q4 20255 holders, $43m29 holders, $27.8bn
Q1 20265 holders, $48m34 holders, $35.6bn
Q2 20267 holders, $396m33 holders, $39.1bn
RARE

Ultragenyx Pharmaceutical In

Holders
5
Reported value
$48m
Buyers
18
Sellers
11

Breadth +7 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RARE (4)

Moore Capital Management LP, PDT Partners LLC, Schonfeld Strategic Advisors LLC, Voloridge Investment Management LLC

Only JNJ (33)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →